Add to ORKGThis article is an invitation to doctors around the world to participate in the CRASH-2 trial (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage), a large, multi-centre, randomised controlled trial of a simple and widely practicable treatment for traumatic hemorrhage. The rationale for the trial and contact details for those who would like to take part are given below. [Introduction
Eff ects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma pat...
Background: The Clinical Randomisation of an Anti-fibrinolytic in Significant Hemorrhage-2 (CRASH-2)...
INTRODUCTION: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsib...
This editorial is an open invitation to trauma doctors to participate in the international CRASH-2 t...
A large randomised placebo controlled trial among trauma patients with or at risk of significant hae...
Antifibrinolytic agents in traumatic haemorrhage: A large-scale randomised controlled trial is neede
There is an urgent need to improve the evidence base for trauma care. Large-scale clinical trials ca...
BACKGROUND: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the r...
Background: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the r...
Every year, more than a million people die as a result of trauma. This huge mortality could be parti...
BACKGROUND: Haemorrhage is a leading cause of death in severe trauma. Fibrinogen plays a critical ro...
This paper reviews the application of tranexamic acid, an antifibrinolytic, to trauma. CRASH-2, a la...
This paper reviews the application of tranexamic acid, an antifibrinolytic, to trauma. CRASH-2, a la...
For people at ages 5 to 45 years, trauma is second only to HIV/AIDS as a cause of death. Each year, ...
In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth...
Eff ects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma pat...
Background: The Clinical Randomisation of an Anti-fibrinolytic in Significant Hemorrhage-2 (CRASH-2)...
INTRODUCTION: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsib...
This editorial is an open invitation to trauma doctors to participate in the international CRASH-2 t...
A large randomised placebo controlled trial among trauma patients with or at risk of significant hae...
Antifibrinolytic agents in traumatic haemorrhage: A large-scale randomised controlled trial is neede
There is an urgent need to improve the evidence base for trauma care. Large-scale clinical trials ca...
BACKGROUND: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the r...
Background: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the r...
Every year, more than a million people die as a result of trauma. This huge mortality could be parti...
BACKGROUND: Haemorrhage is a leading cause of death in severe trauma. Fibrinogen plays a critical ro...
This paper reviews the application of tranexamic acid, an antifibrinolytic, to trauma. CRASH-2, a la...
This paper reviews the application of tranexamic acid, an antifibrinolytic, to trauma. CRASH-2, a la...
For people at ages 5 to 45 years, trauma is second only to HIV/AIDS as a cause of death. Each year, ...
In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth...
Eff ects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma pat...
Background: The Clinical Randomisation of an Anti-fibrinolytic in Significant Hemorrhage-2 (CRASH-2)...
INTRODUCTION: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsib...